Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.1 Covid-19 impact analysis at global level
1.2 Data validation
1.3 Data sources
1.3.1 Primary
1.3.2 Secondary
1.3.2.1 Paid sources
1.3.2.2 Public sources
Chapter 2 Executive Summary
2.1 Plasma derived therapy industry 360° synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Product trends
2.1.3 Application trends
2.1.4 Regional trends
Chapter 3 Plasma Derived Therapy Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 – 2032 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Increasing prevalence of rare diseases
3.3.1.2 Growing demand for advanced therapeutic for treatment of genetic disorders
3.3.1.3 Increase in number of plasma collection centers across the globe
3.3.1.4 Rising adoption of immunoglobulins across the nation
3.3.2 Industry pitfalls and challenges
3.3.2.1 Stringent regulatory policies
3.4 Growth potential analysis
3.4.1 By product
3.4.2 By application
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Plasma Derived Therapy Market Estimates and Forecast, By Product, 2018-2032 (USD Million)
5.1 Key trends, by product
5.2 Immunoglobulins
5.3 Coagulation factors
5.4 Albumin
5.5 Other products
Chapter 6 Plasma Derived Therapy Market Estimates and Forecast, By Application, 2018-2032 (USD Million)
6.1 Key trends, by application
6.2 Hemophilia
6.3 Primary immunodeficiency diseases
6.4 Idiopathic/Immune thrombocytopenic purpura (ITP)
6.5 Other applications
Chapter 7 Plasma Derived Therapy Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Australia
7.4.5 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Rest of Latin America
7.6 Middle East & Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
7.6.4 Rest of Middle East & Africa
Chapter 8 Company Profiles
8.1 CSL Behring
8.2 Takeda Pharmaceutical Company Limited.
8.3 Biotest AG
8.4 Octapharma
8.5 BPL
8.6 ADMA Biologics
8.7 Grifols, SA
8.8 Kedrion
8.9 Kamada Pharmaceuticals.
8.10 SK Plasma
8.11 Pfizer, Inc.
